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Treatment update on acromegaly
Atualização no tratamento da acromegalia
Tatiana Hotimsky Millner1, Lea Lederer Diamant2
REVIEW
ABSTRACT
Pegvisomant is a new drug that blocks growth hormone peripheral
receptors, allowing normalization of insulin-like growth factor-1
levels and consequently of clinical symptoms, reducing morbidity
and mortality associated with acromegaly in almost all patients.
Its introduction made us review the literature aiming to compare
the currently available therapies for acromegaly and their
respective advantages and disadvantages. The treatment
algorithms for this disease were reviewed considering that the
different existing therapies allow more adequate individualization
to each specific case, and addressing cost, availability, efficacy
and safety.
Keywords: Acromegaly/drug therapy; Insulin-like growth factor I;
Acromegaly/surgery; Acromegaly/radiotherapy; Somatostatin;
Octreotide; Dopamine agonists
RESUMO
O pegvisomanto é uma nova droga que atua através do bloqueio
dos receptores periféricos do hormônio de crescimento (GH),
permitindo a normalização dos níveis de fator de crescimento
semelhante à insulina tipo 1 e, conseqüentemente, dos sintomas
clínicos, reduzindo a morbimortalidade associada à acromegalia
na quase totalidade dos pacientes. A sua introdução nos levou a
realizar uma revisão da literatura com o objetivo de comparar as
várias modalidades terapêuticas utilizadas no tratamento da
acromegalia com suas respectivas vantagens e desvantagens. O
algoritmo de tratamento desta doença foi revisto, pois os inúmeros
agentes terapêuticos existentes permitem uma individualização
mais adequada a cada caso específico, levando-se em conta o
custo, disponibilidade, eficácia e segurança.
Descritores: Acromegalia/terapia; Fator de crescimento
semelhante à insulina tipo 1; Acromegalia/cirurgia; Acromegalia/
radioterapia; Somatostatina; Octreotida, Agonistas de dopamina
INTRODUCTION
Acromegaly is a chronic disease caused by excessive
production of growth hormone (GH). Most cases result
from GH hypersecretion by a somatotroph cell
adenoma of the anterior hypophysis. It is rarely caused
by excessive or ectopic secretion of GH releasing
hormone (GHRH) (a hypothalamic hormone that
stimulates GH secretion) or ectopic tumor secretion
of GH. The excessive production of GH before fusion
of epiphyseal cartilages in children or adolescents leads
to pituitary gigantism.
Acromegaly is a rare condition with an incidence
of 3-4 new cases/million inhabitants(1-2) and usually
diagnosed between the 4th and 5th decades of life. It
has an insidious progression, and the interval between
onset of symptoms and diagnosis is approximately 12
years(3). It is very difficult to determine the onset of
the disease and it is usually done by means of old
photographs of patient. Diagnosis is visual and often
made by a physician who is not an endocrinologist. At
diagnosis, approximately 75% of patients have
macroadenomas (tumor diameter = 10 mm), and some
have para- or suprasellar extension; 60% of individuals
complain of headache and 10% present visual
symptoms, classically bitemporal hemianopsia(4).
Virtually all acromegalics present exaggerated growth
of the limbs and soft tissues. The characteristic findings
include macrognathia and macroglossia, growth and
edema of hands and feet that require bigger shoes and
larger rings. Macroglossia, associated with larger soft
tissues in the larynx and pharynx, causes sleep apnea in
up to 50% of cases. The carpal tunnel syndrome due to
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edema in the median nerve is observed in 20% of cases.
The facial features become coarse, with enlarged nose
and frontal bones and widely spaced teeth. Despite the
importance of these findings for diagnosis, the speed of
changes is very slow and few patients seek help due to
alterations in their appearance (only 13% in a series of
256 patients)(4). Other characteristic findings include
hypertrophic arthropaty, heart conditions, such as
systemic arterial hypertension, left ventricle hypertrophy
and cardiomiopathy, hyperhidrosis (present in 50% of
patients) and visceromegaly. Pituitary adenoma may cause
reduced secretion of other hypophyseal hormones,
particularly gonadotrophins. A multi-center study with
363 patients demonstrated that hypogonadism was
observed in 49% of males and 57% of females(5). Women
may have menstrual irregularity, followed or not by
galactorrhea, vasomotor symptoms and vaginal atrophy.
The hypogonadic male patients complain of erectile
dysfunction, altered libido and testicular atrophy. It is
suspected that acromegalic patients have a high
incidence of different types of cancer and pre-malignant
colon polyps. Approximately 10% of patients develop
adenocarcinomas of colon, stomach and esophagus,
apart from melanoma(6) (figure 1).
The diagnosis of acromegaly is proven by frankly elevated
basal GH levels, presence of pituitary tumor and evident
clinical picture, and elevated serum insulin-like growth factor
1 (IGF-1) levels. No GH suppression to levels < 1 mcg/l
after ingestion of 75 grams of oral glucose (GTT) remains
as the golden standard test for diagnosis(7). There is much
controversy regarding acceptable criteria for cure. The current
consensus is that the biochemical criterion for cure is IGF-1
normalization, adjusted by age and sex, associated with
suppression of GH levels to levels < 1 mcg/l after GTT(7).
IGF-1 is produced in the liver through GH stimulus
and represents a secretion marker of this hormone. GH
presents oscillations in 24 hours, whereas IGF-1, for
having a prolonged half-life, is a more sensitive and
specific diagnostic tool of disease activity, and is useful
in the assessment of therapeutic efficacy.
In cases of clinically suspected acromegaly, with low
basal GH levels of and doubtful IGF-1 levels, dynamic
tests are indicated. In such conditions, a GTT is
performed and, together with IGF-1, enable making
diagnosis of the disease and monitoring treatment.
The existence of increasingly more sensitive GH assays
led to changing the levels considered normal during GTT
suppression, which are currently < 0.3 mcg/l(8).
Figure 1. Prevalence of the clinical characteristics of acromegaly at diagnosis
Source: Clemmons DR et al.(11)
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The objectives of acromegaly treatment are
normalization of the biochemical markers of the
disease, eradication or control of tumor mass, with
preserved pituitary function, relief of signs and
symptoms caused by GH excess and reversion of poor
prognosis in the long run.
The importance of biochemical control of the disease
is fundamental because when GH levels are < 2.5 mcg/l,
with normal IGF-1 levels, the mortality rate of acromegalic
patients is similar to that of the general population(9-11).
It should be noted that a significant decrease in IGF-1
levels, but not achieving normalization, is already enough
to improve co-morbidities, such as excessive sweating,
sleep apnea, carpal tunnel syndrome, heart condition and
glycemic control.
The effects of the tumor mass lead to some clinical
manifestations including headache, visual alterations,
hypopituitarism and, more rarely, hypothalamic
dysfunction. Reduced mass effect by controlling tumor
volume is an objective of the treatment, and it is easily
attained by surgical resection. Conventional radiotherapy
has also demonstrated to be effective, but the onset of
action is slow. Among the drugs available for medical
treatment, somatostatin analogues are more effective than
other agents in reducing tumor mass, yet, the result is
not very marked.
The main types of treatment - clinical, radiotherapeutic
and surgical – differ as to efficacy and capacity to preserve
anterior hypophysis function. The latter is undoubtedly a
definite advantage of clinical treatment; however, it should
be compared with other therapies in terms of efficacy,
tolerance and, primarily, costs and risks Figure 2. Shows
an algorithm used in the treatment of this condition.
Figure 2. Treatment algorithm Source: Clemmons DR et al.(11)einstein. 2004; 2(4):324-31
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Advanced surgical technique with selective
resection of the tumor, allow preserving pituitary
function, and recovery of hormone deficiencies
observed before surgery(9-10).
The frequency and severity of hypopituitarism after
conventional radiotherapy are dose-dependent and
increase with time(11). Fifteen to 20% of patients have
evidence of altered pituitary function when initiating
radiotherapy (RT), and the incidence rises to over 50%
after 5 to 10 years(11-12). It is not known yet if the risk
differs in conventional and stereotactic RT.
The metabolic alterations resulting from GH excess
include glucose intolerance or type II diabetes mellitus
(DM), which occur in 25-50% of patients, and lipid
abnormalities(11). Hyperglycemia and reduced glucose
sensitivity consequent to GH anti-insulin effect - improve
by reducing or blocking GH receptors. Hypertriglyceridemia
resulting from decreased activity of hepatic lipoprotein
lipase also resolves with treatment.
SURGERY
Most acromegalic patients are submitted to
transsphenoidal surgery (TSS) as the initial therapy,
leading to significant clinical improvement and substantial
reduction in GH secretion and IGF-1 levels, even in cases
of partial tumor resection. The overall postoperative
remission rate, considering IGF-1 normalization as the
criterion for cure, varies in the literature from 44% to
74%; in cases of microadenomas, it ranges from 84% to
91%, and of macroadenomas, from 48% to 64%(13). When
surgery is performed by an experienced neurosurgeon,
the remission rate may achieve up to 70% of extensive,
non-invasive and well-defined tumors(13).
TSS is the most effective therapy to reduce symptoms
associated with tumor mass, such as optic chiasma
compression. The surgical complications, such as
hypopituitarism, visual loss or permanent diabetes insipidus,
are rare and their incidence is inversely proportional to
the number of surgeries already performed by a professional.
In patients with persistent or recurrent
postoperative GH hypersecretion, the decision about
future treatment should take into account the following
factors: severity of disease, patient’s age and/or duration
of disease, tumor expression of different somatostatin
receptor subtypes, potential for long-term pituitary
damage (young patients at child-bearing age) and risk
of premature death and cardiovascular complications.
RADIOTHERAPY
Radiotherapy (RT) has traditionally played an important
role as an adjuvant treatment for patients not cured by
surgery. However, considering the development of
effective drug therapy for acromegaly, many centers
currently indicate RT only to resistant cases, to patients
who cannot tolerate the medication, or those with
expanded tumor mass despite medical treatment.
Conventional fractionated RT reduces GH levels to
< 5 ug/l in 75% of patients after 15 years(14). Few studies
considered IGF-1 normalization as a criterion for cure.
A meta-analysis compiled by Freda et al. demonstrated
IGF-1 normalization in only 23% of patients after 6 years,
57% of patients after 6 to 10 years, and 89% of patients
after 10 years of follow-up after RT(13).
Hypopituitarism, an important and undesired
radiation side effect, occurs in less than 50% of
cases(12). One or more pituitary hormone deficiencies
were detected in 11% of patients after surgery; in 29%
five years after RT; in 54% ten years after RT; and in
58% over 15 years after RT(12). Although rare, other
complications resulting from RT were development of
secondary CNS malignant diseases, radionecrosis and
visual damage(13).
Gamma-knife RT ha also been used to treat
acromegaly. A recent study reported biochemical
remission in 29% (17 out of 59 patients) in a mean
follow-up period of 27 months (5-98 months)(15).
Approximately 30% of patients developed
hypopituitarism in his relatively short follow-up(15).
Other studies suggested that GH level normalization
with gamma-knife takes place faster than after
conventional RT(16-17). In the studies with a short-follow-
up period, hypopituitarism was observed in only 0 to
16% of patients(18). Nevertheless, data related to
pituitary damage in the long run are not available yet.
DRUG TREATMENT
The drugs available for acromegaly include dopamine
agonists (DA), somatostatin analogues and the newly
launched GH receptor blocker.
3A) Dopamine agonists
These are active agents orally given that bind to D2
receptors in somatotrophs of the anterior hypophysis
and suppress GH secretion in acromegalic patients. The
clinical and biochemical response is extremely variable.
Bromocriptine and cabergoline are the agents most
often used. The tumors co-secreting prolactin present
a more favorable response to treatment(19-20). Although
bromocriptine improve signs and symptoms and reduce
GH in some patients, only 20% (112 out of 549)
achieved GH levels inferior to 5 mcg/l, and only 10%
(12 in 116) attained normal IGF-1 levels in a studyeinstein. 2004; 2(4):324-31
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carried out by Jaffe and Barkan(20). High doses of
bromocriptine, up to 20 mg/day, are usually necessary
to obtain results, causing frequent side effects, which
are an important limiting factor for its use.
Cabergoline, a more recent dopamine agonist, with
a longer half-life, has better efficacy and tolerance as
compared with bromocriptine.
Abs et al. showed that the treatment with
cabergoline during 3 to 40 months led to normalized
IGF-1 levels (defined as IGF-1 < 300 mcg/l) in 35% of
48 patients suffering from tumors that were exclusively
GH secretors, and to GH suppression (< 2 mcg/l) in
44% of them(19). The efficacy of this product was
superior in patients with tumors co-secreting GH and
prolactin (PRL); in that, 50% of cases presented IGF-
1 level normalization and 56% had GH suppression
(< 2 mcg/l). Lower GH and IGF-1 levels before
treatment were associated with greater efficacy. IGF-1
normalization occurred in 43% of patients with levels
< 750 mcg/l before therapy as compared with only 22%
with IGF-1 > 750 mcg/l. Cabergoline dose varied from
1 mg to 1.75 mg/week, and resistant patients required
doses up to 3.5 mg/week.
There are few data in the literature on reduction
of tumor mass by means of dopamine agonists. Jaffe
and Barkan used combined data from several studies
and concluded that out of 62 patients treated with
bromocriptine, 29% had some tumor reduction(20). Most
patients had hyperprolactinemia before treatment. The
study by Abs demonstrated tumor reduction smaller
than 50% in 5 out of 9 patients with macroadenoma(19).
This study also confirmed more tumor reduction in
patients with GH and prolactin co-secreting adenomas.
The side effects more frequently observed with
dopamine agonists are nausea, constipation, headache,
mood disorder and dizziness. Comparative data
demonstrated lower incidence of side effects with
cabergoline as compared to bromocriptine. Abs et al.
reported that only 3% of patients had to discontinue
medication(19). By and large the impairing side effects
of cabergoline are rare and their incidence may be
decreased by slow titration of the dose.
3B) Somatostatin analogues
Since their introduction in the clinical practice,
somatostatin analogues have been the first-choice
therapy in acromegaly. Somatostatin and its analogues
exert their biological effects by activating five different
subtypes of receptors in somatotrophs. In subtypes 2
and 5, endogen GH suppression by somatostatin takes
place; these are the main subtypes expressed in GH
secreting pituitary tumors(21). The somatostatin
analogues available - octreotide and lanreotide – have
selective affinity to receptor 2 and 5 subtypes, but
affinity to subtype 2 is approximately 10-fold greater
than that of subtype 5(22). It is important to mention
that there is no tachyphylaxis in GH secretion inhibition.
A significant percentage of pituitary GH secreting
tumors is resistant to somatostatin analogues. This
characteristic may be partly explained by variation in
tumor expression or decrease in density of subtype 2
and 5 receptors present in the tumor.
Somatostatin analogues lead to effective and safe
suppression of GH and IGF-1 levels. In a recent review,
Freda reported that 56% of patients treated with
octreotide long-acting repeatable (LAR) and 49% of
those treated with lanreotide sustained release (SR)
had an appropriate GH suppression(23). Likewise, IGF-
1 levels drop in 66% and 48% of patients treated with
octreotide LAR and lanreotide SR, respectively(23). It
should be mentioned that approximately 90% of
patients in the studies with octreotide were previously
selected as to octreotide responsiveness, whereas in the
investigations with lanreotide, only 10% of subjects had
been previously selected(23).
Ten to 20% of patients who are resistant to
somatostatin analogues may benefit from its association
with dopamine agonists(24). Sixty-four to 74% of
patients treated with long-duration analogues improved
signs and symptoms of acromegaly, such as headache,
arthralgia, hyperhidrosis, fatigue, edema and carpal
tunnel syndrome in the first six months of therapy(23).
Symptomatic improvement occurs with a drop in GH
and IGF-1 levels, even if they are not completely
normalized. Cardiovascular disease, the main cause of
death in these patients, sleep apnea episodes and
hyperglycemia improved with reduced GH levels(25).
Thirty per cent of patients taking somatostatin
analogues showed a 20-50% reduction in tumor
volume(23,26). The clinical meaning of this decrease has
not been well established, for large reductions are not
necessarily followed up by biochemical control(27).
Furthermore, there is no definite conclusion on tumor
reduction resulting in recovery of pituitary function
that was previously altered.
Somatostatin analogues may be used as primary
treatment of acromegaly in elderly individuals, in patients
at high surgical risk or in those refusing surgery. Data
related to use of somatostatin analogues as primary
therapy demonstrated normalization of IGF-1 levels in
60% and GH suppression in 50% of patients(23,28). These
results are similar to those reported in studies in which
the analogues were used as adjuvant therapy(28). In cases
of visual or neurological impairment, the indication ofeinstein. 2004; 2(4):324-31
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surgery is compulsory, since treatment with analogues may
not lead to significant reduction of the tumor mass, and
relief of pressure in the optic chiasma(23,29).
Circumscribed microadenomas and macroadenomas
present high cure rates when surgery is performed by
an experient professional. In extensive or invasive
tumors, surgery will not be curative; thus, in many cases,
the normalization of IGF-1 levels of 50-60% achieved
with analogues will be greater than that resulting from
surgery. The choice of a non-surgical treatment may
however limit the use of radiotherapy in the future, if
the tumor mass is very close to the optic chiasma.
The somatostatin analogues may also be used in
the preoperative period of transsphenoidal surgery.
Some studies did not demonstrate benefits in this
indication; however, Colao et al. conclude that
preoperative treatment with octreotide, for 3 to 6
months, improved clinical conditions of patients,
surgical results and reduced length of stay at hospital(30).
The somatostatin analogues were used for about
20 years and presented good safety and tolerance. Their
main adverse effects are gastrointestinal symptoms,
including diarrhea, abdominal discomfort, nausea, soft
stools, biliary calculi and sludge. The reactions are often
mild and tend to stop along treatment. Biliary calculus
is often asymptomatic, observed in 15% of patients and
more common in the first year of treatment(23).
The usual dose of octreotide is 100-400 mcg,
subcutaneously (SC), every 8 hours. Octreotide LAR,
a long duration formulation, requires intramuscular
(IM) administration by a healthcare professional. The
dose varies from 20 to 30 mg, every 28 days, and causes
a persistent GH suppression that may last for up to 7
weeks(31). Lanreotide SR is administered IM, 30 mg,
every 7 to 14 days, or deep SC (Autogel), every 28 days.
3C) Pegvisomant (Peg)
It is a new drug that has been recently approved for
use in the US and Europe, and it acts by blocking GH
peripheral receptors.
The success of a surgery depends on experienced
surgeons, who are not available in all cities, as well as
on the anatomy and invasion grade of a tumor.
Radiotherapeutic response depends on radiation
sensibility and tumor anatomy, which defines the type
of radiation to be applied. The efficacy of conventional
clinical treatment has been limited by existence and
density of dopamine and/or somatostatiergic receptors.
In turn, Peg blocks the action of GH in peripheral
receptors, regardless the tumor characteristics.
The primary biochemical objective of the treatment
with Peg is normalization of IGF-1 levels. GH levels
cannot be used as markers of disease activity in these
patients because they may rise in the first two weeks of
treatment, which is not considered clinically significant.
Trainer, in a randomized, double-blind, controlled study
of 112 patients with active acromegaly described IGF-
1 level normalization in 89% of patients receiving Peg
20 mg/day, SC, for 12 weeks(32). The treatment resulted
in significant improvement in clinical and biochemical
acromegalic manifestations (edema, hyperhidrosis and
fatigue).
Van der Lely et al. conducted a longer study on the
use of Peg and reported normalization of IGF-1 levels
in 97% of 90 patients treated for longer than 12 months
with doses of up to 40 mg/day(33). Symptomatic
improvement was found during all observational period.
Apart from symptomatic improvement, the long-
term treatment with Peg leads to correcting metabolic
alterations from acromegaly. Drake studied patients
who switched form octreotide to Peg and showed better
glucose tolerance and insulin sensitivity, even with no
changes in body composition and similar IGF-1
levels(34). The somatostatin analogues had complex and
unpredictable effects in glucose tolerance due to
potent insulin and glucagon secretion inhibition,
resulting in improved glucose tolerance through better
control of GH/IGF-1 axis or worse tolerance. A recent
randomized study compared the effects of octreotide
and Peg in insulin release after a standardized meal.
Octreotide led to inhibited insulin release and
postprandial hyperglycemia, but Peg caused no
alterations(35).
The major doubt about using Peg in acromegalic
treatment is a possible growth of the pituitary tumor.
In a study mentioned above, the author did not report
significant alteration in mean tumor volume in 131
patients treated approximately for one year, with
follow-up visits and RM every 6 months even in
individuals who had not been previously submitted to
RT(33). During therapy with Peg, two patients presented
tumor growth; however, this sign had been already
recorded before treatment. The growth rate of pituitary
tumors is extremely variable and makes it difficult to
assess the effect of Peg treatment.
The use of Peg in gigantism seems to be a very
promising alternative. Barkan treated two children with
pituitary gigantism with Peg; they had not been submitted
to RT due to their age and had an inappropriate response
to octreotide LAR.(36) Both presented normalization of
IGF-1 levels, interrupted somatic growth, had no side
effects and no tumor growth. Complete growth
interruption was observed during this treatment. A better
management of these patients is required to maintain
growth speed appropriate for their age.einstein. 2004; 2(4):324-31
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The main side effect of Peg treatment is reversible
changes in hepatic enzymes(11). Two patients presented
reversible increase in SGOT/SGPT levels in the first 12
weeks of treatment(11). There were no significant changes
in bilirubin levels. Hence, hepatic function monitoring is
essential in all patients initiating treatment with Peg.
Self-limited reactions on the injection application sites
may occur, and were reported in 11% of patients(11).
The disadvantages of Peg include its high cost and
the fact it requires high compliance of patients to
chronic treatment.
CONCLUSION
The introduction of Peg, a new drug that acts by blocking
GH peripheral receptors, enables IGF-1 level
normalization and symptomatic improvement, thus
reducing the morbidity and mortality rates of acromegaly
in almost all patients. There are still some controversies
about increased tumor volume when using this medication.
Therefore, we decided to review the algorithms used in
the treatment of this condition (figure 2). Circumscribed
microadenomas and macroadenomas should be referred
to surgery due to great likelihood of cure. In extensive or
invasive tumors, somatostatin analogues may be used as
first-choice therapy, aiming to improve the clinical
conditions of patients and/or to reduce tumor volume
before submitting patients to surgery. Up to a few years
ago, the next step for patients not cured by surgery would
be RT, because there were no drugs available. RT may cure
75% of patients after a very long period, sometimes of
approximately 15 years, with high complication rates. It is
an affordable treatment in our country and its costs are
lower than that of drug therapy.
After a surgery in which cure for acromegaly was
not achieved, or in cases the surgery is contraindicated
or refused, if there are economic resources available, a
clinical treatment with dopamine agonists, somatostatin
analogues or Peg may be used. These therapies do not
lead to cure, require continuous administration and
are extremely expensive. Among the three agents, Peg
presents the highest normalization rate of IGF-1 levels
and symptoms. If normalization of IGF-1 levels is not
achieved or if the medical treatment has many side
effects, another surgical intervention or
radiotherapeutic treatment should be considered.
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